Relations of Serum COMP to Cardiovascular Risk Factors and Endothelial Function in Patients with Rheumatoid Arthritis Treated with Methotrexate and TNF-α Inhibitors
Authors:
- Gunnbjørg HjeltnesGHGunnbjørg Hjeltnes
- Ivana HollanIHIvana Hollan
- Øystein FørreØFØystein Førre
- Allan WiikAWAllan Wiik
- Torstein LybergTLTorstein Lyberg
- Knut MikkelsenKMKnut Mikkelsen
- Stefan AgewallSAStefan Agewall
- 1 June 2012
- journal article
- research article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 39 (7) , 1341-1347
Abstract
Objective.: To examine whether serum level of cartilage oligomeric matrix protein (S-COMP) is related to methotrexate (MTX) or to MTX and tumor necrosis factor-α (TNF-α) combination treatment for rheumatoid arthritis (RA); and to investigate whether S-COMP is related to cardiovascular risk factors including endothelial dysfunction and level of anticitrullinated protein antibodies (ACPA) in patients with RA.Methods.: Clinical and laboratory measures, including S-COMP and reactive hyperemic index (RHI), were examined in 55 consecutive patients with RA starting with either MTX (n = 34) or MTX and anti-TNF-α treatment (n = 21) at baseline, and after 6 weeks and 6 months.Results.: S-COMP was similar in the 2 treatment regimens during followup. We found a positive relationship between S-COMP at baseline and the use of disease-modifying antirheumatic drugs the last year preceding the study (p = 0.001), and a negative relation to current use of systemic glucocorticosteroids (p = 0.044). The nonsignificant change in S-COMP between baseline and the 6-month followup was positively and independently related to change in ACPA level (p = 0.009). There was no significant association between RHI and level of S-COMP at baseline.Conclusion.: The cartilage turnover marker S-COMP did not change significantly after 6 months’ treatment with MTX with or without a TNF-α inhibitor in patients with RA. The positive association between S-COMP and ACPA suggests that these factors might interact, and could both be contributors to an unknown link between inflammation and cartilage destruction in patients with RA. S-COMP was not related to endothelial function in patients with RA, or to other cardiovascular risk factors studied. Clinical Trials registration numberNCT00902005.Keywords
This publication has 29 references indexed in Scilit:
- Cartilage oligomeric matrix proteinAfCS-Nature Molecule Pages, 2010
- A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt studyAnnals of the Rheumatic Diseases, 2010
- High Serum Cartilage Oligomeric Matrix Protein Determines the Subset of Patients with Early-Stage Rheumatoid Arthritis with High Serum C-Reactive Protein, Matrix Metalloproteinase-3, and MRI-Proven Bone ErosionThe Journal of Rheumatology, 2009
- Cartilage and Bone Biomarkers in Rheumatoid Arthritis: Prediction of 10-year Radiographic ProgressionThe Journal of Rheumatology, 2009
- Rheumatoid arthritisThe Lancet, 2009
- Value of serum cartilage oligomeric matrix protein as a prognostic marker of large-joint damage in rheumatoid arthritis--data from the RAPIT studyRheumatology, 2008
- Prognostic laboratory markers of joint damage in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2005
- Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanerceptArthritis Research & Therapy, 2003
- Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism.Journal of Clinical Investigation, 1995
- CARTILAGE OLIGOMERIC MATRIX PROTEIN: A NOVEL MARKER OF CARTILAGE TURNOVER DETECTABLE IN SYNOVIAL FLUID AND BLOODRheumatology, 1992